Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 7:06 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 7,829 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Acute Disease Clear all

Conditions: Multiple Sclerosis
Interventions: Methylprednisolone, Prednisone; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Ischemic Stroke
Interventions: Computed tomography perfusion imaging; Other
Lead sponsor: California Pacific Medical Center Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Acute Coronary Syndrome, Depression, Myocardial Infarction, Unstable Angina, STEMI, NSTEMI - Non-ST Segment Elevation MI
Interventions: Individual Interview; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 35 Years to 85 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Fractures, Closed, Pain, Postoperative, Pain Catastrophizing, Pain, Acute, Analgesia, Opioid Use, Acceptance and Commitment Therapy, Orthopedics, Analgesics, Opioid, Text Messaging
Interventions: Acceptance and Commitment Therapy Delivered via an Automated Mobile Messaging Robot; Behavioral
Lead sponsor: Christopher Anthony; Other
Eligibility: 18 Years to 100 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: COVID-19, Acute Kidney Injury, Chronic Kidney Injury
Interventions: Not listed
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 1,753 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 5
States / cities: New Haven, Connecticut • Baltimore, Maryland • Ann Arbor, Michigan + 2 more

Conditions: Acute Ischemic Stroke
Interventions: Concentric Retriever Device; Device
Lead sponsor: Sidney Starkman; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Spondylolisthesis
Interventions: Not listed
Lead sponsor: Zimmer Biomet; Industry
Eligibility: 20 Years to 80 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: No Disease or Condition is Being Studied
Interventions: CBG Intervention, Placebo Intervention; Dietary Supplement · Other
Lead sponsor: Washington State University; Other
Eligibility: 21 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Pullman, Washington

Conditions: Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Biphenotypic Leukemia, Acute Undifferentiated Leukemia, CLL (Chronic Lymphocytic Leukemia), Chronic Myeloid Leukemia (CML), MDS (Myelodysplastic Syndrome), Non-Hodgkin Lymphomas, Hodgkins Lymphoma, Cutaneous T Cell Lymphomas (CTCL)
Interventions: Ossium HPC Marrow, Bone Marrow Transplant, Pre-transplant conditioning - Myeloablative (MAC), Pre-transplant conditioning - Reduced Intensity (RIC), Post-transplant treatment; Other
Lead sponsor: Ossium Health, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 9
States / cities: Duarte, California • Tampa, Florida • Atlanta, Georgia + 6 more

Conditions: Leukemia, Myeloid, Acute, Minimal Residual Disease
Interventions: Not listed
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Blepharitis
Interventions: NCX 4251, Placebo; Drug
Lead sponsor: Nicox Ophthalmics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Urinary Incontinence
Interventions: Urodynamic testing with and without pudendal nerve stimulation; Diagnostic Test
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years to 85 Years · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 2
States / cities: Royal Oak, Michigan

Conditions: Acute Schizophrenia, Schizoaffective Disorder
Interventions: RP5063, placebo, aripiprazole; Drug
Lead sponsor: Reviva Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Acute Bacterial Skin and Skin Structure Infections
Interventions: sodium fusidate, linezolid; Drug
Lead sponsor: Arrevus Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 716 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 60
States / cities: Anaheim, California • Bakersfield, California • Buena Park, California + 46 more

Conditions: Post Operative Pain, Acute, Periodontitis
Interventions: Dexamethasone IV injection, Dexamethasone Capsule, Placebo IV administration, Placebo capsule; Drug · Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Hereditary Angioedema (HAE)
Interventions: ecallantide, Phosphate Buffer Saline (PBS),; Drug
Lead sponsor: Shire; Industry
Eligibility: 10 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Wheaton, Maryland

Conditions: Migraine Disorders
Interventions: Combination Product (sumatriptan succinate / naproxen sodium), Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 26
States / cities: Fresno, California • Newport Beach, California • Santa Monica, California + 23 more

Conditions: B-cell Acute Lymphoblastic Leukemia
Interventions: NGS-MRD, Myeloablative allogeneic HCT with a non-TBI conditioning regimen; Diagnostic Test · Drug
Lead sponsor: Pediatric Transplantation & Cellular Therapy Consortium; Other
Eligibility: 1 Year to 25 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 24
States / cities: Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 19 more

Conditions: Prediabetic State
Interventions: Stair Climbing Frequency; Behavioral
Lead sponsor: Jennifer Gay; Other
Eligibility: 40 Years to 64 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Athens, Georgia

Conditions: COVID, Covid-19, Coronavirus, Coronavirus Infection, Severe Acute Respiratory Syndrome, Severe Acute Respiratory Syndrome Coronavirus 2, Sars-CoV2, Ards, Acute Respiratory Distress Syndrome
Interventions: APL-9, Vehicle Control; Drug · Other
Lead sponsor: Apellis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 16
States / cities: Fresno, California • San Francisco, California • Jacksonville Beach, Florida + 12 more

Conditions: Respiratory Distress Syndrome, Adult
Interventions: Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells, Plasma-Lyte A; Biological
Lead sponsor: Michael A. Matthay; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 6
States / cities: San Francisco, California • Stanford, California • Boston, Massachusetts + 3 more

Conditions: Monoclonal B-Cell Lymphocytosis, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, B-cell Non Hodgkin Lymphoma, Hodgkin Lymphoma
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Secondary Acute Myeloid Leukemia
Interventions: nonmyeloablative allogeneic hematopoietic stem cell transplantation, fludarabine phosphate, total-body irradiation, cyclosporine, mycophenolate mofetil, peripheral blood stem cell transplantation; Procedure · Drug · Radiation
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 55 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 2
States / cities: Portland, Oregon • Seattle, Washington

Conditions: COVID-19, Coronavirus, Coronavirus Infection
Interventions: INOpulse, Placebo; Combination Product
Lead sponsor: Bellerophon Pulse Technologies; Industry
Eligibility: 18 Years and older
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 17
States / cities: Phoenix, Arizona • San Diego, California • Miami, Florida + 8 more

Search by objective public record fields.

Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques

The PERFusion Use in Stroke Evaluation Study

MBCT Delivered Via Group Videoconferencing for ACS Patients With Elevated Depression Symptoms

Pain and Narcotic Usage After Orthopaedic Surgery

Kidney Disease After COVID-19

Concentric Retriever Device (CRD) in Acute Ischemic Stroke

Posterior Lateral Fusion (PLF) With Dynesys

Acute Psychological and Physiological Effects of Cannabigerol

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies

Development and Application of a Novel Digital Array PCR for Acute Myeloid Leukemia (AML)

Study Evaluating the Safety and Efficacy of NCX 4251 Ophthalmic Suspension for the Treatment of Blepharitis

Acute Pudendal Nerve Stimulation On Leak Point Pressure In Women Urodynamic Early Feasibility Study

RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder

Oral Sodium Fusidate (CEM-102) Versus Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections

The Effect of Dexamethasone on Short Term Patient Response: IV vs Oral Administration

Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)

A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)

The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

Pilot Stair Climbing Study

A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19

Human Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (START)

Immunogenicity and Safety of Commercially Available Vaccines Against SARS-CoV-2 (COVID-19) in Patients With Hematologic Malignancies

Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission

A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19